Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection
Stroke induces brain injury, especially severe in hypertensive patients, and elevates mortality rates through non-neurological complications. However, the potential effects of a transient ischaemic episode on the peripheral vasculature of hypertensive individuals remain unclear. We investigated whether transient cerebral ischaemia (90 min)/reperfusion (1 or 8 days) induces alterations in mesenteric resistance artery (MRA) properties in adult male spontaneously hypertensive rats (SHR). In addition, we assessed whether the reported cerebroprotective effects of suberoylanilide hydroxamic acid (SAHA; 50 mg/kg; administered intraperitoneally at 1, 4, or 6 h after reperfusion onset) extend over several days and include beneficial effects on MRAs. Functional and structural properties of MRAs were examined at 1- and 8-days post-stroke. Nuclei distribution, collagen content, and oxidative stress were assessed. Ischaemic brain damage was evaluated longitudinally using magnetic resonance imaging. Following stroke, MRAs from SHR exhibited non-reversible impaired contractile responses to the thromboxane A<sub>2</sub> receptor agonist U46619. Stroke increased the MRA cross-sectional area, wall thickness, and wall/lm ratio due to augmented collagen deposition. These changes were partially sustained 8 days later. SAHA did not improve U46619-induced contractions but mitigated stroke-induced oxidative stress and collagen deposition, preventing MRA remodelling at 24 h of reperfusion. Furthermore, SAHA induced sustained cerebroprotective effects over 8 days, including reduced brain infarct and oedema, and improved neurological scores. However, SAHA had minimal impact on chronic MRA contractile impairments and remodelling. These findings suggest that stroke causes MRA changes in hypertensive subjects. While SAHA treatment offers sustained protection against brain damage, it cannot fully restore MRA alterations.
Authors
- Clara Penas (ORCID: https://orcid.org/0000-0003-0554-3832)
- María Rodriguez-Garcia (ORCID: https://orcid.org/0000-0002-7080-1060)
- Silvia Lope‐Piedrafita (ORCID: https://orcid.org/0000-0002-8127-6425)
- Belén Pérez (ORCID: https://orcid.org/0000-0001-5801-1704)
- Francesc Jiménez‐Altayó (ORCID: https://orcid.org/0000-0002-9034-2041)
- Ana M. Briones (ORCID: https://orcid.org/0000-0001-8218-5579)
- Xavier Navarro (ORCID: https://orcid.org/0000-0001-9849-902X)
- Paula Vázquez-Sufuentes
- Andrea Díaz-Pérez
Institutions
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red (ES)
- Institut d'Investigacions Biomèdiques de Barcelona (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Life Sciences
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1016/j.lfs.2024.123247
- Citations
- 1
- Primary Topic
- Neurological Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.25
Funders
- European Commission
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- Departament de Salut, Generalitat de Catalunya
- Agencia Estatal de Investigación
- Spanish National Plan for Scientific and Technical Research and Innovation